← All companies

Gilead Sciences

3 reports

Research on this company

Goldman Sachs

Goldman Sachs: Gilead strengthens oral immunology pipeline with $1.275 billion deal, while combination prospects depend on early-stage development

Gilead plans to acquire PepStar’s oral IL-23R inhibitor program, adding a piece to its all-oral combination strategy for inflammatory bowel disease. Goldman Sachs acknowledges the long-term strategy, but the lead asset remains in Phase I with no efficacy data publicly disclosed, and the deal will also reduce fourth-quarter earnings per share.